drugset
drugset / Trial / NCT05947201

Neoadjuvant Treatment of Cadonilimab Combined Albumin-paclitaxel, Cisplatin and Fluorouracil for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

NCT05947201 ↗

Phase 2 Unknown 26 enrolled Weijia Fang, MD Akeso Pharmaceuticals, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a single-arm clinical study to evaluate the efficacy and safety of Cadonilimab in combination with preoperative chemotherapy for locally advanced esophageal squamous cell carcinoma Locally Advanced Esophageal Squamous Cell Carcinoma

Timeline

Start
2023-05-08
Primary completion
2024-03-01
Completion
2024-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Cadonilimab Monoclonal antibody 10 mg/kg Intravenous
Background Albumin paclitaxel Unknown 100 mg/m2 Intravenous
Background Cisplatin Other / unclassified 20 mg/m2 Intravenous
Background fluorouracil Small molecule 600 mg/m2 Intravenous

Indications

No indication recorded.